Successful treatment of C. auris shunt infection with intraventricular caspofungin

Medical Mycology Case Reports
Tanu SinghalRajeev Soman

Abstract

C. auris is an emerging fungal pathogen with high prevalence of resistance to current antifungal agents. Central nervous system infection with C. auris has been infrequently described. We describe here an adult with nosocomial CSF shunt infection due to multi drug resistant C. auris. Systemic therapy with echinocandin and flucytosine failed. Fortunately, administration of daily intraventricular caspofungin 10 mg for 10 days in conjunction with systemic voriconazole resulted in both clinical and microbiological cure.

Citations

Mar 29, 2019·Current Opinion in Infectious Diseases·Karen C Bloch, Samuel S Bailin
Feb 19, 2019·Mycoses·Shabir A Lone, Aijaz Ahmad
Aug 20, 2019·Internal Medicine Journal·Chong W OngUNKNOWN Australian and New Zealand Mycoses Interest Group (ANZMIG); and the Healthcare Infection Control Special Interest Group (HIC
May 1, 2020·Clinical Microbiology Reviews·Roland NauHelmut Eiffert
May 23, 2020·Infection and Drug Resistance·Muluneh Ademe, Friehiwot Girma

❮ Previous
Next ❯

Software Mentioned

VITEK

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.